Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of biomarkers in normal bowel by Fernandez-rozadilla, Ceres et al.
 
 
Telomere length and genetics are independent
colorectal tumour risk factors in an evaluation of
biomarkers in normal bowel
Fernandez-rozadilla, Ceres; Kartsonaki, Christiana; Woolley, Connor; Mcclellan, Michael;
Whittington, Deb; Horgan, Gareth; Leedham, Simon; Kriaucionis, Skirmantas; East, James;
Tomlinson, Ian
DOI:
10.1038/bjc.2017.486
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Fernandez-rozadilla, C, Kartsonaki, C, Woolley, C, Mcclellan, M, Whittington, D, Horgan, G, Leedham, S,
Kriaucionis, S, East, J & Tomlinson, I 2018, 'Telomere length and genetics are independent colorectal tumour
risk factors in an evaluation of biomarkers in normal bowel', British Journal of Cancer, vol. 118, no. 5, pp. 727-
732. https://doi.org/10.1038/bjc.2017.486
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Telomere length and genetics are
independent colorectal tumour risk factors in
an evaluation of biomarkers in normal bowel
Ceres Fernandez-Rozadilla1, Christiana Kartsonaki2, Connor Woolley1, Michael McClellan3, Deb Whittington4,
Gareth Horgan4, Simon Leedham4,5, Skirmantas Kriaucionis3, James East3 and Ian Tomlinson*,1,6
1Molecular and Population Genetics Laboratory University of Oxford, Oxford OX3 7BN, UK; 2Clinical Trial Service Unit and
Epidemiological Studies Unit, Nuffield Department of Population Health, Old Road Campus, Oxford OX3 7DQ, UK; 3Ludwig
Institute for Cancer Research, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK;
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Background: Colorectal cancer (CRC) screening might be improved by using a measure of prior risk to modulate screening
intensity or the faecal immunochemical test threshold. Intermediate molecular biomarkers could aid risk prediction by capturing
both known and unknown risk factors.
Methods: We sampled normal bowel mucosa from the proximal colon, distal colon and rectum of 317 individuals undergoing
colonoscopy. We defined cases as having a personal history of colorectal polyp(s)/cancer, and controls as having no history of
colorectal neoplasia. Molecular analyses were performed for: telomere length (TL); global methylation; and the expression of
genes in molecular pathways associated with colorectal tumourigenesis. We also calculated a polygenic risk score (PRS) based on
CRC susceptibility polymorphisms.
Results: Bowel TL was significantly longer in cases than controls, but was not associated with blood TL. PRS was significantly and
independently higher in cases. Hypermethylation showed a suggestive association with case:control status. No gene or pathway
was differentially expressed between cases and controls. Gene expression often varied considerably between bowel locations.
Conclusions: PRS and bowel TL (but not blood TL) may be clinically-useful predictors of CRC risk. Sample collection to assess these
biomarkers is feasible in clinical practice, especially where population screening uses flexible sigmoidoscopy or colonoscopy.
Colorectal carcinoma (CRC) is one of the most common forms of
malignancy (Ferlay et al, 2013). It is considered a complex disease,
with both inherited and environmental factors involved in
predisposition (Houlston and Peto, 2004). Genome-wide associa-
tion studies (GWAS) have so far identified over 30 common
polymorphisms (SNPs) associated with CRC and adenoma risk in
the general population (Broderick et al, 2007; Tomlinson et al,
2007, 2008, 2011; Houlston et al, 2008, 2010; Tenesa et al, 2008;
Dunlop et al, 2012; Whiffin et al, 2014).
Screening for benign polyps and their removal by colonoscopy
can reduce CRC risk (Zauber et al, 2012). Many European
countries now offer population screening programmes, based
primarily on faecal occult blood tests (FOBT) (Robertson and
Imperiale, 2015). Despite the effectiveness of these programmes,
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the burden of screening is likely to increase considerably and CRC
will continue to be a major killer. It would therefore be useful to
improve screening by targeting it to those at highest risk.
Individualised risk prediction is generally infeasible outside the
Mendelian CRC syndromes (Dunlop et al, 2013). It remains
possible, however, that risk prediction is still clinically useful when
applied to population-level screening because of nthe following
reasons: (i) the unknown and/or unmeasurable risks are distributed
among large numbers of individuals and (ii) population stratifica-
tion by prior risk is an improvement on the current screening that
is targeted solely by age.
Another potentially useful measure of disease risk is the
intermediate molecular phenotype, since this can hypothetically
capture both known and unknown factors that act through a
common mechanism. For example, there are at least 7 CRC SNPs
with putative effects on bone morphogenetic protein (BMP)
signalling, and a measure of BMP pathway activity might,
therefore, capture the effects on BMP signalling of the following:
(i) these SNPs, (ii) other unknown SNPs, (iii) rare variants in the
same pathway, and (iv) unknown environmental factors. Other
intermediate phenotypes with potential effects on CRC risk include
telomere length (TL) (von Zglinicki, 2002) and DNA methylation
(Ehrlich, 2002). These phenotypes have usually been assessed in a
more convenient sample such as peripheral blood, rather than in
the bowel itself. While many biomarkers have been postulated to
predict CRC risk (Ishihara et al 2008), most of these are not
established risk factors and there exist relatively few previous
studies of intermediate molecular markers (Alexander et al, 2017).
The polygenic risk score (PRS) – a quantitative score of
susceptibility caused by common genetic variants (Dudbridge,
2013) – is another measure of CRC risk that may be clinically
useful (Machiela et al, 2011). The predictive value of the CRC PRS
has been assessed in previous studies (Dunlop et al, 2013;
Frampton et al, 2016). However, these have only considered
carcinoma risk and none included polyps or performed a
prospective assessment.
In this study, we have searched for associations between a set of
candidate intermediate molecular markers and case:control status
in individuals undergoing colonoscopic screening for colorectal
tumours. We have also assessed a PRS based on the major CRC
predisposition SNPs. Our results have potential importance and
clinical applicability for risk prediction models that can be used to
modulate population screening for CRC.
MATERIALS AND METHODS
Patients and samples. Colorectal biopsies were obtained from 317
individuals of white UK origin undergoing colonoscopy in Oxford.
Indications for colonoscopy included: family history of CRC
(N¼ 15); symptoms compatible with CRC (N¼ 164); follow-up for
previous polyps/CRC (N¼ 97); FOBT-positive UK National Bowel
Cancer Screening patients (N¼ 91), and rectal prolapse or
diverticulitis (N¼ 16). B3mm3 biopsies of normal bowel
epithelium were taken from up to three sites (rectum, distal colon
and proximal colon), together with 10ml peripheral blood.
Personal and family histories of bowel disease and the basic
demographic data were recorded. Participants were placed into one
of the following three categories: (1) polyp cases—individuals with
personal history of adenomatous and/or serrated polyps; (2) CRC
cases—individuals with personal history of carcinoma; and (3)
controls—individuals with no polyps or CRC in the present or
past. Individuals not fulfilling these criteria or with other
pathologies, such as inflammatory bowel disease, were excluded
(Table 1). Ethical approval was obtained from the Oxfordshire
Research Ethics Committee A (REC 10/H0604/72). All patients
provided informed consent, according to the tenets of the
Declaration of Helsinki.
DNA/RNA extraction. Each biopsy was submerged in RNAlater
(Life Technologies). DNA and RNA were extracted with the
AllPrep DNA–RNA Mini kit (Qiagen, Manchester, UK). Where
multiple biopsies had been taken from the same patient, each
individual biopsy was analysed, except that for assays in which a
single DNA-based measure per patient was required, where an
aliquot of DNA from each available location was pooled in equal
proportions. For RNA samples, an aliquot was DNase-treated and
reverse transcribed into cDNA. We estimated the typical ratio of
epithelium–to–mesenchyme in biopsies to be 1:1.
Two-stage design. Participants were recruited in two stages: Phase
1 (54 cases and 47 controls was collected between November 2012
and July 2013 based on the indications described above for
colonoscopy; replication Phase 2, comprising 157 cases and 59
controls, was collected between July 2013 and March 2014 based
on the same criteria. Phase 1 was analysed for all DNA and RNA
markers (Supplementary Methods). In Phase 2, all patients were
analysed for all the DNA-based markers, and a subset of 103 cases
and all controls were analysed for the expression of genes that had
evidence in Phase 1 of an association with case:control status at a
nominal P¼ 0.05.
Telomere length assays. We assessed telomere length (TL) in
blood and bowel DNA in 262 patients using a modification of
Cawthon´’s method (Cawthon, 2009; Jones et al, 2012). DNA
samples were run in duplicate on a CFX96 system (Bio-Rad,
Watford, UK). A curve was established relating the quantity of a
standard DNA to DCt for the telomere repeat and a single-copy
gene (gamma haemoglobin). This provided the expected Ct value
(ECt) for the telomere repeat. Corrected Ct (CorrDCt) was
calculated by subtracting ECt from observed (OCt), providing a
relative measure of telomere length. CorrDCt was always 40 and
the higher the CorrDCt, the longer the telomere.
Genomic DNA methylation assay. Global DNA methylation
analyses were performed using reverse-HPLC (Quinlivan and
Gregory, 2008) by measuring total 5-methylcytosine (5mC)
content in 136 patients. Briefly, 2500 ng genomic DNA were
RNase-treated in NEB2.1 buffer and incubated for 1 h at 37 C,
purified with ethanol and lyophilised. The sample was re-
suspended in 50 ml RNase-free water and hydrolysed overnight in
a solution containing 45mM NaCl, 9mM MgCl2, 9mM Tris pH 7.9,
X250U/ml 1 Benzonase (Sigma), 50mU/ml 1 Phosphodiester-
ase I, X20U/ml 1 Alkaline phosphatase, 46.8 ng/ml 1 EHNA
hydrochloride, 8.64 mM deferoxamine. Protein components were
removed with Amicon centrifugal filter units (3 kDa cutoff,
Millipore, Watford, UK) and resolved with an Agilent UHPLC
1290 (Stockport, UK) instrument fitted with Eclipse Plus C18
RRHD 1.8 mm, 2.1 150mm column. Buffer A was 100mM
ammonium acetate, pH 6.5; buffer B was 40% acetonitrile, and
the flow rate 0.4mlmin 1. The gradient was between 1.8 and 100
Table 1. Numbers of patients included in the study by case
N Male/
female
Mean age (SD),
range
Clinical
phenotype (N)
Phase 1 Controls 47 24/23 54 (17.3), 22–80
Cases 54 33/21 67 (8.2), 42–84 A (46), CRC (8)
Phase 2 Controls 59 27/32 52 (16.4), 21–83
Cases 157 79/78 65 (9.4), 30–89 A (79), S (37),
CRC (41)
Abbreviations: A¼ adenoma; CRC¼ colorectal carcinoma; S¼ serrated polyp; SD¼
standard deviation. Numbers of patients included in the study by case:control status, sex,
age, and tumour histology.
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of 40% acetonitrile. Methylation was also assayed in blood and
bowel DNA separately.
Molecular pathway activity assessment. Using real-time, quanti-
tative PCR (qPCR), eight molecular pathways were investigated,
which were either related to CRC development or reflecting cellular
processes linked to tumourigenesis (Supplementary Table 1). To
assess these, we identified 33 genes as pathway end points. Gene
expression assays were conducted on an ABI900HT real-time
instrument (Applied Biosystems, Foster City, CA, USA), using
TaqMan (ThermoScientific, Waltham, MA, USA) molecular
probes. As per the recommendations in the current qPCR
guidelines, we optimised the normalisation procedure by choosing
the best-suited set of housekeeping genes. Given that a literature
search did not yield did not yield any unambiguous results, we
tested 11 endogenous genes (Supplementary Table 1). The optimal
set for normalisation was identified using qBaseþ . Normalisation
was then carried out, using a DDCt method for relative
quantification.
SNP genotyping and polygenic risk scores. KASPar genotyping
technology (LCGenomics) was used to generate a 25 SNP genotype
profile of each of 310 patients (Supplementary Table 2). PRSs were
calculated for the 293 patients with X22 successfully genotyped
SNPs according to:
logSðbiNiÞÞ25
i¼1
where b is the Ln(odds ratio) for each risk allele and N is the
number of risk alleles. The missing data points were substituted by
the population mean.
Statistical analyses. These were performed with Stata-v.11
(StataCorp LP, TX, USA) and R (http://www.r-project.org/). For
gene expression analysis, individual genes were assessed for
associations with case:control status using linear regression fitted
with generalised estimated equations (GEE). The activity of each
pathway was then generated by carrying out principal component
analysis on all gene expression variables for that pathway, and
taking the first principal component as a summary pathway value.
For DNA phenotypes (TL and methylation), logistic regression was
fitted, adjusting by age, sex, phase and experimental batch, where
appropriate. Where possible, differences between cases and
controls were also evaluated separately for each of the three
locations in the large bowel. False discovery rate (FDR) corrections
were performed using the Benjamini & Hochberg method
(Benjamini and Hochberg, 1995) and significance was assumed
at FDR-corrected q¼ 0.05. Results are reported below as a meta-
analysis of the two Phases, unless otherwise specified. Given the
absence of evidence of heterogeneity between Phases, all variables
associated with case:control status at nominal P¼ 0.05 were then
included in a reverse stepwise multivariable logistic regression
analysis, and variables associated with case:control status at
P¼ 0.05 were retained in the final model. Case-only analyses used
multivariate logistic regression models including age, sex and
phase.
RESULTS
Telomere length. After conditioning on age, which co-varied with
telomere length as expected, there was an association between
longer TLs in the bowel and case status (Pmeta¼ 0.003; OR¼ 2.18;
95% CI¼ 1.30–3.67; ORQ1vsQ4¼ 1.92; 95% CI¼Q1vsQ4¼ 0.87–
4.26). Effects in Phases 1 and 2 were consistent (Figure 1). We
found no significant difference in bowel TL between the following
patients: (i) with polyps at the recruitment colonoscopy or
previously (P¼ 0.590), (ii) with and without a history of CRC
(P¼ 0.284), (iii) with polyps or CRC (P¼ 0.211), and (iv) with
present or previous CRC (P¼ 0.664). TL was also independent of
family history of colorectal neoplasia (P¼ 0.201). Within-patient
analysis showed no significant variation in bowel TL by location
(Supplementary Figure 1), and this remained true when comparing
within-patient TL in biopsies from locations close to the polyp/
CRC, compared with those further away (P¼ 0.436 for proximal
colon, P¼ 0.591 for distal colon, P¼ 0.055 for rectum).
Of note, blood TL was associated with neither case:control
status (P¼ 0.989, OR¼ 1.00, 95% CI¼ 0.88–1.14) nor bowel TL
(P¼ 0.195, OR¼ 1.06 95% CI¼ 0.97–1.15; Supplementary
Figure 2), although both bowel and blood TL were negatively
correlated with age (P¼ 0.000, r2¼  0.03; and P¼ 0.000,
r2¼  0.04, respectively).
Methylation. Global methylation (5mC) levels, as assessed from
pooled DNA derived from all three colorectal regions, increased
with age as expected (P¼ 4 10 5; OR¼ 1.09; 95% CI¼ 1.05–
1.14). We observed a suggestive, but non-significant, increase in
global methylation levels in cases compared with controls
(Pmeta¼ 0.070; OR¼ 1.58; 95% CI¼ 0.96–2.64; Supplementary
Figure 3). Blood 5mC was assayed in a subset of 31 samples, but
there was no good evidence of a correlation with bowel 5mC
(P¼ 0.139; OR¼ 0.94; 95% CI¼ 0.86–1.02; r2¼  0.27; Supple-
mentary Figure 4). As for TL, we did not find any significant
differences between patients with present or past polyps (P¼ 0.44),
with or without family history (P¼ 0.117), polyps or CRC
(P¼ 0.259) or present vs previous CRC (P¼ 0.117), and methyla-
tion levels were independent of family history (P¼ 0.304).
Analyses by location showed significantly lower methylation in
the proximal colon compared to the distal colon or the rectum
(Supplementary Figure 5). Analyses using only the location-specific
measurements of methylation did not yield any significant
associations (data not shown).
Gene expression analysis. We assayed 273 samples from 100
patients for 33 selected genes from 8 pathways (Supplementary
Table 1). There was an effect of location on gene expression, with
18 out of 33 genes differentially expressed (at qp0.05) between the
proximal and distal colon, 21 out of 33 between the proximal colon
and rectum, and 16 out of 33 between the distal colon and rectum
(Supplementary Figure 6); some genes showed monotonically
decreased (ID1, ID3, OLFM4, PLK1) or increased (AXIN2, CCND1,
CDK6, E2F1, EPHB2, ID2, KCNH2, KCNMA1, LRIG1, MCM2,
PCBP4, SCNN1D, SCNN1G, TFDP1) levels along the proximal
colon-distal colon-rectum axis (Supplementary Figure 7). Correla-
tions between the expression of gene pairs are depicted in
Supplementary Figure 8. Case:control status was not significantly
associated with the expression of any individual gene at a nominal
Pp0.05 (Supplementary Table 3). Pathway analysis revealed
nominally higher expression of colonocyte differentiation markers
in cases (P¼ 0.010, q¼ 0.080; Supplementary Table 4).
We then examined bowel location-specific gene expression in
cases who had one or more tumours in that location vs controls
with no colorectal tumour anywhere. Cases with distal colon
tumour(s) had significantly higher SCNN1A expression in that
location than controls (P¼ 0.004; q¼ 0.032; OR¼ 4.09; 95%
CI¼ 1.56–10.76, Supplementary Figure 9). This gene showed no
evidence of association with status in the other locations and no
additional significant associations were found for other genes.
With regards to pathway expression by location, colonocyte
differentiation and Wnt levels were higher in cases in the proximal
colon (q¼ 0.040 for both). Stem cell markers and ion channels
showed varying expression levels depending on the bowel segment
(Supplementary Table 4).
Assessment of SNP genotypes, bowel TL and status. In logistic
regression analysis conditioning on age, sex and family history,
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PRS was significantly higher in cases than controls (P¼ 0.031;
OR¼ 51.1; 95% CI¼ 1.45–1803; per quartile OR¼ 1.22;
Supplementary Figure 10). PRS was not significantly correlated with
bowel TL, methylation or, interestingly, family history (P¼ 0.134,
P¼ 0.114 and P¼ 0.640, respectively, full data not shown).
Two of the three telomerase SNPs were significantly associated
with bowel TL (for rs10936599, P¼ 0.161; for rs2736100,
P¼ 0.009; for rs2735940, P¼ 0.001; non-parametric trend test;
Supplementary Figure 11) and also independently with case:control
status. No other SNP was associated with case:control status
(details not shown).
In reverse stepwise logistic regression analysis, PRS (P¼ 0.046;
OR¼ 63.5; 95% CI¼ 1.08–3740) and bowel TL (P¼ 0.026;
OR¼ 1.74; 95% CI¼ 1.07–2.82) were significantly and indepen-
dently of greater magnitude in cases than controls.
DISCUSSION
In this study, we examined whether intermediate molecular
phenotypes derived from the bowel mucosa were associated with
case:control status in a series of individuals undergoing colono-
scopic screening for colorectal neoplasia. Such molecular markers
potentially predict CRC risk and could be used to modulate
population screening. Our principal finding was that cases with
colorectal polyps or CRC had longer bowel telomeres, independent
of other risk factors. There is a controversy about the effects of
telomere length on the risk of many cancers, including CRC (Quin
et al, 2014; Seguı´ et al, 2014), but almost all studies have measured
telomere length in peripheral blood. Our finding of no correlation
between telomere length in the colorectum and blood may help to
explain the inconsistent results of previous studies. Despite the
assay’s speed and simplicity, telomere measurements from the
mixed population of cells in peripheral blood may be inappropriate
for predicting cancer risk.
SNPs rs2736100 and rs2735940 near TERT and rs10936599 near
TERCf have been associated with CRC risk (Houlston et al, 2010;
Kinnersley et al, 2012; Yang et al 2015), but associations with
normal bowel TL length have not been explored. rs2735940 and
rs2736100 were significantly associated with bowel TL and each
was also independently associated with case:control status,
consistent with previous reports (Hofer et al, 2012).
It has been posited that hypermethylation, resulting from ageing
or environmental causes, is a cause of increased cancer risk
(Ehrlich, 2002). However, most studies have investigated methyla-
tion levels in circulating blood cells. In our study, we found
borderline significant differences in global methylation levels
between cases and controls. A true association might have been
missed due to the fact that our global methylation measure was too
general and did not sufficiently capture finer differential methyla-
tion patterns in CpG islands and other regions. In addition, the
proximal colon had significantly less methylation than the distal
colon and rectum, potentially influencing tumourigenic pathways
in the different regions of the large bowel (Bufill, 1990).
Gene expression analysis throughout the colorectum detected
no significant associations with case:control status for individual
genes, and only a nominal association for molecular pathways in
the case of colonocyte differentiation markers. Given the non-
uniform gene expression patterns observed throughout the bowel
for many of the genes analysed (LaPointe et al, 2008), we
performed association analyses in each location independently and
found that expression of SCNN1A in the distal colon was different
between cases and controls. SCNN1A is a potential marker of
differentiation and encodes a membrane calcium channel that
plays an essential role in maintaining the osmotic gradient in the
intestinal epithelium. We were a little surprised, given the
importance of variation in the BMP pathway for CRC risk,
that we found no evidence of differential activity in this
pathway between cases and controls. Many explanations are
possible, including limited assay sensitivity, sub-optimal choice of
target genes, and spatial and temporal heterogeneity in gene
expression.
Our study’s conclusions should be interpreted in the light of
limitations and potential confounding factors. While the associa-
tion between status and bowel TL could have been caused by the
presence of tumour(s) rather than vice versa, we found no evidence
of this, as there were no significant differences between TL in cases
with incident CRC or polyps and previous tumours. Moreover, it
seems unlikely that polyps could have major effects on sampled
normal mucosa that can be more than a metre away in the large
bowel, and indeed we did not observe significant intra-patient
differences when comparing TL in biopsies close to and distant
from a tumour. Second, the fact that both gene expression and
global methylation vary throughout the large bowel suggests that
location-specific risk models may be more powerful. Our
exploratory analyses (details not shown) have demonstrated that
because patients frequently have polyp(s) in only one bowel
location, location-specific risk models are required with larger
sample sets in order to provide adequate statistical power. Third,
we caution that, although we deliberately used simple biopsies
without the separation of epithelium and mesenchyme, because
these represent the sample type most likely to be available in a
clinical setting, our measurements were derived from a mixed
cellular population, potentially affecting all assays except the PRS.
Fourth, the performance of the PRS is likely to be improved in the
future by taking into account recently discovered predisposition
loci (Zeng et al, 2016, amongst others) and polymorphisms specific
to the risks of adenomas, serrated polyps and CRC.
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Figure 1. Association of colorectal telomere length with case:control status. (A) Beeswarm plot of CorrDCt TL values corrected for age in cases
and controls with overlying boxplot; (B) Forest plot for meta-analysis of TL. CI¼ confidence interval; TL¼ telomere length.
BRITISH JOURNAL OF CANCER Telomeres, SNPs and colorectal tumour risk
730 www.bjcancer.com |DOI:10.1038/bjc.2017.486
In summary, we have shown the potential value of using
intermediate molecular markers, and the independent value of the
PRS, for predicting colorectal tumour risk. Our data also show the
virtues of using biomarkers derived from the colorectum rather
than blood. Bowel cancer screening programmes are increasingly
using colonoscopy or flexible sigmoidoscopy as a primary modality
and rectal biopsies could be obtained safely from participants at
limited cost and subjected to molecular analyses that could then be
incorporated into algorithms for subsequent screening. While
additional studies are required, we suggest that stratification by
prior risk could offer a way to improve the cost-effectiveness of
population-level large bowel cancer screening populations, whether
by prioritising patientsat highest risk or modulating thresholds for
further investigation after screening by FIT.
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